SEC Comment Letter for PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648) (PVLA) — Aug 15, 2018
PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648)
Date: Aug. 15, 2018 · CIK: 0001583648 · Accession: 0000000000-18-025274
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226725
Letter
August 15, 2018 Stephen S. Yoder Chief Executive Officer Pieris Pharmaceuticals, Inc. 255 State Street, 9th Floor Boston, MA 02109 Re:Pieris Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 9, 2018 File No. 333-226725 Dear Mr. Yoder: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jonathan Burr at 202-551-5833 with any questions. Sincerely, Division of Corporation Finance Office of Beverages, Apparel and Mining cc: William C. Hicks
Show Raw Text
August 15, 2018
Stephen S. Yoder
Chief Executive Officer
Pieris Pharmaceuticals, Inc.
255 State Street, 9th Floor
Boston, MA 02109
Re:Pieris Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 9, 2018
File No. 333-226725
Dear Mr. Yoder:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jonathan Burr at 202-551-5833 with any questions.
Sincerely,
Division of Corporation Finance
Office of Beverages, Apparel and
Mining
cc: William C. Hicks